XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements and Investments (Tables)
6 Months Ended
Mar. 31, 2025
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Assets and Liabilities Measured at Fair Value on a Recurring Basis
 Fair Value Measurements
Using Inputs Considered as
 Level 1Level 2
 March 31,
2025
September 30,
2024
March 31,
2025
September 30,
2024
 (in millions)
Assets
Cash equivalents and restricted cash equivalents:
Money market funds
$9,438 $10,403 $ $— 
U.S. Treasury securities
7  — 
Investment securities:
Marketable equity securities
314 301  — 
U.S. government-sponsored debt securities
 — 305 496 
U.S. Treasury securities
2,868 4,948  — 
Other current and non-current assets:
Money market funds
27 25  — 
Derivative instruments
 — 194 103 
Total $12,654 $15,684 $499 $599 
Liabilities
Accrued compensation and benefits:
Deferred compensation liability
$235 $238 $ $— 
Accrued and other liabilities:
Derivative instruments
 — 252 226 
Total $235 $238 $252 $226 
Schedule of Amortized Cost, Unrealized Gains and Losses, and Fair Value of Debt Securities
The amortized cost, unrealized gains and losses and fair value of debt securities were as follows:
March 31, 2025
Amortized
Cost
Gross UnrealizedFair
Value
GainsLosses
(in millions)
U.S. government-sponsored debt securities$303 $$— $305 
U.S. Treasury securities2,858 17 — 2,875 
Total$3,161 $19 $ $3,180 
September 30, 2024
Amortized
Cost
Gross UnrealizedFair
Value
GainsLosses
(in millions)
U.S. government-sponsored debt securities$492 $$— $496 
U.S. Treasury securities4,920 40 (5)4,955 
Total$5,412 $44 $(5)$5,451 
Schedule of Debt Securities Classified by Contractual Maturity Date
The stated maturities of debt securities were as follows:
March 31,
2025
 (in millions)
Due within one year$1,789 
Due after one year through five years
1,391 
Total$3,180 
Schedule of Non-Marketable Equity Securities
The following table summarizes the Company’s non-marketable equity securities held as of period end that were accounted for using the fair value measurement alternative:
March 31,
2025
September 30,
2024
(in millions)
Initial cost basis
$702 $711 
Adjustments:
Upward adjustments
850 910 
Downward adjustments, including impairment
(494)(465)
Carrying amount
$1,058 $1,156 
Unrealized gains and losses of the Company’s non-marketable equity securities held as of period end that were accounted for using the fair value measurement alternative were as follows:
Three Months Ended
March 31,
Six Months Ended
March 31,
2025202420252024
(in millions)
Upward adjustments$7 $— $7 $
Downward adjustments, including impairment
$(31)$(15)$(49)$(15)